Original Paper

Journal of Autism and Developmental Disorders

, Volume 38, Issue 2, pp 324-332

Are There Enhanced MBP Autoantibodies in Autism?

  • Jane E. LibbeyAffiliated withDepartment of Neurology, University of Utah
  • , Hilary H. CoonAffiliated withDepartment of Psychiatry, University of Utah
  • , Nikki J. KirkmanAffiliated withDepartment of Neurology, University of Utah
  • , Thayne L. SweetenAffiliated withDepartment of Neurology, University of Utah
  • , Judith N. MillerAffiliated withDepartment of Psychiatry, University of Utah
  • , Edward K. StevensonAffiliated withDepartment of Neurology, University of Utah
  • , Janet E. LainhartAffiliated withDepartment of Psychiatry, University of Utah
  • , William M. McMahonAffiliated withDepartment of Psychiatry, University of Utah
  • , Robert S. FujinamiAffiliated withDepartment of Neurology, University of Utah Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Autoantibodies to central nervous system antigens, such as myelin basic protein (MBP), may play a role in autism. We measured autoantibody titers to MBP in children with autism, both classic onset and regressive onset forms, controls (healthy age- and gender-matched) and individuals with Tourette syndrome via enzyme-linked immunosorbent assays. We found a significant difference in autoantibody titers to MBP, not accounted for by age or medication, between Tourette and classic autism (both significantly lower) when compared to regressive autism, but not when compared to controls. Autoantibody responses against MBP are unlikely to play a pathogenic role in autism.

Keywords

Autism Tourette syndrome Autoantibody Myelin basic protein Immunoglobulin